Antithrombin I Activity

Summary

1. Our experiments demonstrate that antithrombin I interferes considerably in the thrombin inhibitor determination described by Jürgens. A similar interference can be suspected in the immediate antithrombin determinations as described by other investigators in experiments based on the same principle.

2. The thrombin-adsorbing capacity of fibrin depends to a high degree on the ionic strength of the medium: low ionic strength enhances, while high concentrations inhibite antithrombin J activity.

3. After allowing for antithrombin I interference in the total thrombin inhibition, there was still measurable direct antithrombin activity present. The magnitude of the latter is directly correlated to the antithrombin capacity found in plasma samples free of the antithrombin I side-effect. Such plasma samples were obtained from a patient with congenital afibrinogenemia and heat-defibrinated normal plasma.

 

^*) Associé du Fonds National de la Recherche Scientifique, Belgium.

• References

• 1 Burstein M. Sur l’effet antithrombinique de l’héparine. Rôle de la concentration en héparine. C. R. Soc. Biol. (Paris) 1952; 146: 641
• 2 Burstein M, et Loeb J. Sur l’effet antithrombinique de l’héparine. Rôle du pH, de la concentration saline et des ions alcalino-terreux. C. R. Soc. Biol. (Paris) 1952; 146: 250
• 3 Nilsson I. M, Wenckert A. Demonstration of a heparin-like anticoagulant in normal blood. I. Human blood. Acta med. scand 1954; 150 suppl 297
• 4 Wenckert A, Nilsson I. M. Thromboplastin and Russell Viper venom. Scand. J. clin. Lab. Invest 1955; 7 suppl 15
• 5 Graham J. B, Barrow E. M. The pathogenesis of hemophilia. An experimental analysis of the anticephalin hypothesis in hemophilic dogs. J. exp. Med 1957; 106: 273
• 6 Jürgens J. Neue Bestimmungsmethoden und Bedeutung der Antithrombine für die Klinik. Klin. Wschr 1957; 35: 303
• 7 Schultze H. E, Schwick G. Laboratoriums-Blätter Behringwerke Nr. 1953: 2
• 8 Owren P.A. The coagulation of blood. Oslo: 1947
• 9 Kaulla K. N. Autoaktivierung und Autofibrinolyse. Eine einfache Schnellmethode zur Gewinnung hochaktiven, menschlichen Materials. Klin. Wschr 1957; 35: 667
• 10 Florkin M, en Massart M. Medische Biochemie. N. V. Standard-Boekhandel; Antwerpen: 1944
• 11 Philips G. E, Weiner M, Gilman L, Lenahan J. G. Non specific factors in blood coagulation. J. Lab. clin. Med 1955; 46: 644
• 12 Stormorken H, Newcomb T. F. The use of buffers in blood coagulation studies. Scand. J. clin. Lab. Invest 1956; 8: 237
• 13 Astrup T. Biochemistry of blood coagulation. Acta physiol. scand 1944; 7 suppl 21
• 14 Loeliger A, Hers J. F. Chronic Antithrombinaemia (Antithrombin V) with haemorrhagic diathesis in a case of rheumatoid arthritis with hypergammaglobulinaemia. Thromb. Diath. haem 1957; 1: 499
• 15 Vandenbroucke J, Verstraete M, Verwilghen R. L’afibrinogénémie congénitale. Présentation d’un nouveau cas et revue de la literature. Acta haemat. (Basel) 1954; 12: 87
• 16 Burstein M. Sur le pouvoir antithrombinique de l’héparine. Thrombose und Embolie. p. 303 Benno Schwabe; Basel: 1954
• 17 Astrup T, Darling Sv. Antithrombin and heparin. Acta physiol. scand 1943; 5: 13
• 18 Seegers W. H. Multiple protein interactions as exhibited by the blood-clotting mechanism. J. Phys. Coll. Chem 1947; 51: 198
• 19 Witte S, Dirnberger P. Antithrombin und Thrombininhibitor. Klin. Wschr 1953; 31: 598
• 20 Schmid J. Methode zur Bestimmung der Thrombininhibitoraktivität. Wien. Z. inn. Med 1951; 32: 108
• 21 Usteri C. Das Heparin-Komplement und seine physiologisch-klinische Bedeutung. Inaugural-Dissertation; Zürich: 1949